2015
Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes
Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. Journal Of Diabetes Science And Technology 2015, 9: 639-643. PMID: 25883166, PMCID: PMC4604546, DOI: 10.1177/1932296815578881.Peer-Reviewed Original ResearchConceptsRapid-acting insulin analoguesType 2 diabetesMeal tolerance testPlasma insulin levelsInsulin analoguesInsulin levelsGlucose excursionsInjection siteInsulin absorptionType 2 diabetic patientsPostmeal glucose excursionsStandardized liquid mealPostprandial glucose excursionsTime-action profilePostprandial glucose controlInsulin therapyDiabetic patientsGlucose controlLiquid mealOvernight fastInsulin aspartTolerance testPostprandial hyperglycemiaPremeal bolusesPremeal injections
2010
The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, Meltzer D, Kollman C, Laffel L, Tamborlane W, Weinzimer S, Wysocki T, . The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care 2010, 33: 1269-1274. PMID: 20332354, PMCID: PMC2875436, DOI: 10.2337/dc09-2042.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioContinuous glucose monitoringType 1 diabetic patientsImproved glucose controlCost-effectiveness analysisGlucose controlDiabetic patientsGlucose monitoringBenefits of CGMType 1 diabetes complicationsTest strip useType 1 diabetesCost-effectiveness ratioStandard glucose monitoringMicrovascular complicationsDiabetes complicationsTrial populationSocietal cost-effectiveness analysisGlycemic benefitsLong-term effectsMAIN OUTCOMELife benefitsQALY thresholdStrip useTrial data
2005
Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies
Weinzimer SA, Doyle EA, Tamborlane WV. Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies. Clinical Pediatrics 2005, 44: 393-403. PMID: 15965545, DOI: 10.1177/000992280504400503.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdolescentAdolescent BehaviorAdultAge FactorsAgedAttitude to HealthBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin ResistanceMaleMiddle AgedPatient CompliancePatient Education as TopicPrognosisRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsYoung diabetic patientsGlycemic controlDiabetic patientsType 1 diabetes mellitusContinuous subcutaneous insulin infusionPresence of hypoglycemiaSubcutaneous insulin infusionType 2 diabetesDisease managementContinuous glucose-monitoring systemPositive treatment outcomesGlucose-monitoring systemInsulin glargineYounger patientsDiabetes mellitusHypoglycemic episodesJuvenile patientsNocturnal hypoglycemiaInsulin infusionTreatment outcomesTreatment strategiesCareful monitoringDiabetesPatientsGlucose monitoring
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints